Andrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.
Andrew T. Kuykendall, M
Advertisement
Articles by Andrew T. Kuykendall, M
Advertisement
Latest Updated Articles
Dr. Kuykendall on Toxicity Profiles of Ruxolitinib and Fedratinib in MyelofibrosisPublished: February 21st 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5